Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin versus active comparator for pediatric acute bacterial skin and skin structure infections
2014-005281-30Phase 3Terminated
- Sponsor
- Allergan
- Start
- Sep 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI), Staphylococcal skin infection and sepsis (2 arms), sponsored by Allergan. Primary endpoint: Safety. Started Sep 2016; status: terminated.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)Staphylococcal skin infectionsepsis
Beyond the preview
Go deeper on 2014-005281-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005281-30.